Solid tumor

China’s CAR-T Therapy Emerging in Glioma Treatment: Neurosurgery Team Wins Three International Awards

**China’s CAR-T Therapy Emerging in Glioma Treatment: Neurosurgery Team Wins Three International Awards** At the recently concluded 76th International Exhibition of Ideas, Inventions, and New Products (IENA) in Nuremberg, Germany, a Chinese neurosurgery research team achieved remarkable success. Their independently developed project, the “Fourth-Generation Dual-Target Optimized CAR-T Cell Therapy Platform for Neuro-oncology,” stood out among Read More

November 10th,2024 CAR-T , Solid tumor

Exceptional Efficacy of CAR-T Therapy in China: Disease Control Rate for Advanced Liver Cancer Reaches 78% to 91.3%

### Exceptional Efficacy of CAR-T Therapy in China: Disease Control Rate for Advanced Liver Cancer Reaches 78% to 91.3% #CARTTherapy #LiverCancer #SolidTumors In recent years, China has made remarkable advances in CAR-T cell therapy, particularly demonstrating exceptional potential in liver cancer treatment. CAR-T cell therapy, or chimeric antigen receptor T-cell therapy, involves genetically engineering a Read More

November 8th,2024 Solid tumor , CAR-T

China Overcomes Solid Tumor Challenge: CAR-T Technology IM96 Leads Innovation in Colorectal Cancer Treatment

**China Overcomes Solid Tumor Challenge: CAR-T Technology IM96 Leads Innovation in Colorectal Cancer Treatment** #IM96 #CART #ColorectalCancer #CARTtherapy #ESMO #2024ASCO #SolidTumor China has made remarkable progress in the field of innovative cancer treatment. In October 2024, a Chinese biotechnology company announced that IM96 CAR-T cell injection, developed in collaboration with Peking University Cancer Hospital, received clinical trial approval from the Read More

November 5th,2024 Solid tumor , CAR-T

Revolutionizing Cancer Treatment: China’s Groundbreaking CAR-T Therapy Targets Glioblastoma

Revolutionizing Cancer Treatment: China’s Groundbreaking CAR-T Therapy Targets Glioblastoma #CAR_Therapy #Glioblastoma #CancerResearch #InnovativeMedicine A Chinese medical team has recently made significant progress in t he field of CAR-T cell therapy, bringing new hope for the treatment of solid tumors such as glioblastoma (GBM). While CAR-T therapy has achieved great success in treating hematologic al malignancies, Read More

October 22nd,2024 Solid tumor , CAR-T

China`s Breakthrough TIL Therapy GT201 Shows Remarkable Results in Advanced Solid Tumor Treatment: 100% Disease Control Rate, 69% Tumor Reduction

**China`s Breakthrough TIL Therapy GT201 Shows Remarkable Results in Advanced Solid Tumor Treatment: 100% Disease Control Rate, 69% Tumor Reduction** #TILTherapy #GT201 #SolidTumor #TIL #ASCO2024 Recent research results indicate that the next-generation gene-edited TIL (Tumor-Infiltrating Lymphocyte) therapy, GT201, independently developed by Chinese biotech company GRIT Biotechnology, has shown significant potential in combating various advanced solid tumors. Through a unique Read More

September 23rd,2024 Solid tumor

The CAR-γδT cell therapy QH104, independently developed by a Chinese team, has demonstrated a 100% disease control rate in patients with relapsed glioblastoma

**The CAR-γδT cell therapy QH104, independently developed by a Chinese team, has demonstrated a 100% disease control rate in patients with relapsed glioblastoma.** #glioblastoma #CARγδT #QH104 #γδT #B7H3 #rGBM #CARgammaT A groundbreaking CAR-γδT cell therapy, QH104, developed by a Chinese team, is gaining attention in the global medical community for its potential in treating relapsed glioblastoma (rGBM). Targeting B7H3, QH104 is Read More

September 20th,2024 Solid tumor , CAR-T

Chinese ADC Drug Targeting B7-H3 Approved for Clinical Trials!

Chinese ADC Drug Targeting B7-H3 Approved for Clinical Trials! #ADC #Immunotherapy#B7H3 #LungCancer #HeadAndNeckCancer #ADCDrug On September 20, the China National Medical Products Administration (NMPA) approved BeiGene’s innovative anti-cancer drug, BGB-C354, for clinical trials. This exciting news marks the first approval for clinical research of this novel molecule in China. BGB-C354 is an Antibody-Drug Conjugate (ADC) specifically Read More

September 20th,2024 Solid tumor

The Lancet | Chinese Medical Team: A New Breakthrough in the Treatment of Limited-stage Small Cell Lung Cancer!

The Lancet | Chinese Medical Team: A New Breakthrough in the Treatment of Limited-stage Small Cell Lung Cancer! High-dose Accelerated Hyperfractionated Radiotherapy Helps Improve Treatment Efficacy #SCLC #SmallcelllungCancer #LungCancer #Lancet #LSSCLC Small-cell lung cancer (SCLC) is a highly aggressive malignancy, accounting for 15% of all lung cancer cases. Among these, one-third are diagnosed with limited-stage Read More

September 19th,2024 Solid tumor

Published in Cell Journal | Breakthrough in dMMR Metastatic Colorectal Cancer Treatment: Chinese Research Garners International Recognition

**Published in Cell Journal | Breakthrough in dMMR Metastatic Colorectal Cancer Treatment: Chinese Research Garners International Recognition** #ColorectalCancer #PD1Antibody #dMMR #cell #cellpress #Med #PD-1 #CellJournal A Chinese medical team has made a significant breakthrough in the treatment of dMMR (deficient mismatch repair) metastatic colorectal cancer. Recently, their latest research findings were published in the *Med* journal, Read More

September 13th,2024 Solid tumor

“Curing” the Untouchable Cancer – Systemic Lupus Erythematosus: Chinese Experts Take a Major Leap Forward

**”Curing” the Untouchable Cancer – Systemic Lupus Erythematosus: Chinese Experts Take a Major Leap Forward** #LupusTreatment #HopeForLupus #lupus #AutoimmuneDisease #ChinaHealthcare #SystemicLupusErythematosus #Erythematosus Once hailed as a revolutionary therapy in the field of oncology, Chimeric Antigen Receptor T-cell (CAR-T) therapy is now demonstrating extraordinary potential in the treatment of Systemic Lupus Erythematosus (SLE). For this troublesome Read More

September 11th,2024 Solid tumor , CAR-T

**Breaking News!  China’s Cancer Drug Outperforms Global PD-1 Inhibitor!**

**Breaking News!  China’s Cancer Drug Outperforms Global PD-1 Inhibitor!** #AK112 #CancerDrug #PD-1 #PD1Inhibitor #CancerTreatment #BispecificAntibody #NSCLC China’s pharmaceutical industry has reached a historic milestone! Remember AK112 (Ivonescimab), which took center stage during this year’s ASCO conference, attracting global attention for its groundbreaking potential? The long wait is finally over, and the results are in! In May, Akeso Biopharma, a leading Read More

September 10th,2024 Solid tumor

**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors**

**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors** #MonoclonalADC #Nectin4 #Solidtumor #9MW2821 #cervicalcancer #urothelialcarcinoma #esophagealcancer #breastcancer Meet 9MW2821, a groundbreaking monoclonal antibody-drug conjugate (ADC) developed in China that targets Nectin-4, an adhesion molecule highly expressed in several solid tumors, including cervical cancer (CC), urothelial carcinoma (UC), esophageal cancer Read More

September 5th,2024 Solid tumor